Search Results - "Knott, Aine"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Developing SHP2-based combination therapy for KRAS-amplified cancer by Li, Tianxia, Kikuchi, Osamu, Zhou, Jin, Wang, Yichen, Pokharel, Babita, Bastl, Klavdija, Gokhale, Prafulla, Knott, Aine, Zhang, Yanxi, Doench, John G, Ho, Zandra V, Catenacci, Daniel Vt, Bass, Adam J

    Published in JCI insight (08-02-2023)
    “…Gastroesophageal adenocarcinomas (GEAs) harbor recurrent amplification of KRAS, leading to marked overexpression of WT KRAS protein. We previously demonstrated…”
    Get full text
    Journal Article
  5. 5

    Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma by Ananthapadmanabhan, Varsha, Frost, Thomas C, Soroko, Kara M, Knott, Aine, Magliozzi, Brianna J, Gokhale, Prafulla C, Tirunagaru, Vijaya G, Doebele, Robert C, DeCaprio, James A

    Published in JCI insight (08-07-2022)
    “…Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin with 2 etiologies. Merkel cell polyomavirus (MCPyV) integration is present in…”
    Get full text
    Journal Article
  6. 6

    Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines by Ananthapadmanabhan, Varsha, Knott, Aine, Soroko, Kara M., Gokhale, Prafulla C., Tirunagaru, Vijaya, Doebele, Robert, DeCaprio, James A.

    Published in Molecular cancer therapeutics (01-12-2021)
    “…Abstract Background: MCC is a highly aggressive neuroendocrine carcinoma of the skin with a poor overall prognosis. Current treatment options include surgery…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Abstract C020: Unconvering the hidden immunosuppressive landscape in pancreatic ductal adenocarcinoma by Qian, Guhan, Zhang, Hongrong, Knott, Aine, Zettervall, Jon, Stromnes, Ingunn, Provenzano, Paolo

    Published in Cancer research (Chicago, Ill.) (16-01-2024)
    “…Abstract Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest forms of cancer with an extremely low survival rate. Despite the success of therapeutic…”
    Get full text
    Journal Article
  9. 9
  10. 10